COVID-19 vaccines: Will pandemic partnerships help manufacturers meet global demand?

Posted by Kristyn Feldman on Fri, Jun 05, 2020

Samaya Krishnan, Parul Rewari, Michelle Choi, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

Across the world, the COVID-19 pandemic has touched every continent except Antarctica. With approximately 380,000 deaths worldwide attributed to COVID-19, countries, organizations and companies have come together in an unprecedented manner to develop globally accessible therapeutics and vaccines. With experts citing the need to vaccinate between 50 to 80% of the world’s 7.8 billion people to control the pandemic, creating around six billion doses of any successful vaccine candidate poses some unique challenges.


>
Read More

Current and past trends in life sciences deal-making activity

Posted by Michelle Choi on Fri, May 29, 2020

Cody Powers and Christopher Shapiro co-wrote this blog post with Michelle Choi.

Access COVID-19 resources

In our last blog post, we introduced a framework to assess the impact of COVID-19 on life sciences transaction activity. We noted that, in general, transaction volume declines following recessions and market uncertainty, but there’s evidence to suggest total deal value in these cases has been less affected vs. volume, with significant larger deals observed during prior down periods. In this post, we aim to further analyze these trends and assess how they can help inform the life sciences deal-making landscape today.


>
Read More

COVID-19 vaccines: Who might win the race to the global market?

Posted by Kristyn Feldman on Fri, May 15, 2020

Samaya Krishnan, Parul Rewari, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

In the face of the COVID-19 pandemic, the world is racing to find a safe and effective vaccine for the SARS-CoV2 virus, and industry and academic researchers have initiated clinical trials across the world to test various candidates. In upcoming blogs, we will explore the different vaccine technologies in clinical development, along with where they originated and where they might be tested and manufactured.


>
Read More

Are we seeing a plateau in new entrants to the COVID-19 clinical pipeline?

Posted by Kristyn Feldman on Tue, May 05, 2020

Parul Rewari, Edwin Reyes, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

We are closely watching the evolving clinical trial landscape for COVID-19, and each week the staggering volume of trials continues to increase. Last week, we saw the familiar addition of a large number of new trials1 but noticed that the number of unique assets2 may be plateauing: While many assets are adding additional trials across new geographies, the number of new entrants into the race to address the novel coronavirus may be slowing down (figure 1).


>
Read More

If COVID-19 clinical trial numbers are increasing, why are some studies closing?

Posted by Edwin Reyes on Fri, Apr 24, 2020

Access COVID-19 resources

Kristyn Feldman, Parul Rewari, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Edwin Reyes.

Researchers are racing to set up clinical trials to evaluate a huge variety of treatments and vaccines for COVID-19. Over the past few weeks, as we began to see a “flattening of the curve” in some places, we also observed the stopping of several COVID-19 clinical trials. Why are these trials being stopped? To date, two reasons for the termination of the clinical trials have surfaced:


>
Read More